Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C
I Fernández, R Muñoz-Gómez, JM Pascasio… - Journal of …, 2017 - Elsevier
Background & Aims The development of direct-acting antiviral agents (DAAs) is a major step
forward in the treatment of hepatitis C (HCV). The aims of the study were to evaluate the …
forward in the treatment of hepatitis C (HCV). The aims of the study were to evaluate the …
Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C
I Fernández, R Muñoz-Gómez… - Journal of …, 2017 - journal-of-hepatology.eu
Background & Aims The development of direct-acting antiviral agents (DAAs) is a major step
forward in the treatment of hepatitis C (HCV). The aims of the study were to evaluate the …
forward in the treatment of hepatitis C (HCV). The aims of the study were to evaluate the …
[引用][C] Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C
I Fernández, R Muñoz-Gómez… - Journal of …, 2017 - produccioncientifica.ucm.es
Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
I Fernández, R Muñoz-Gómez, JM Pascasio… - Journal of …, 2016 - europepmc.org
Methods Hepa-C is a Spanish registry of patients treated with DAAs in which clinical,
virological and analytical data were prospectively included. We report on the data from 103 …
virological and analytical data were prospectively included. We report on the data from 103 …
Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C
I Fernández, R Muñoz-Gómez, JM Pascasio… - Journal of …, 2017 - infona.pl
The development of direct-acting antiviral agents (DAAs) is a major step forward in the
treatment of hepatitis C (HCV). The aims of the study were to evaluate the efficacy and …
treatment of hepatitis C (HCV). The aims of the study were to evaluate the efficacy and …
Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
I Fernández, R Muñoz-Gómez, JM Pascasio… - 2017 - cabidigitallibrary.org
Abstract Background & Aims: The development of direct-acting antiviral agents (DAAs) is a
major step forward in the treatment of hepatitis C (HCV). The aims of the study were to …
major step forward in the treatment of hepatitis C (HCV). The aims of the study were to …
Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C
I Fernández, R Muñoz-Gómez… - Journal of …, 2017 - pubmed.ncbi.nlm.nih.gov
Background & aims The development of direct-acting antiviral agents (DAAs) is a major step
forward in the treatment of hepatitis C (HCV). The aims of the study were to evaluate the …
forward in the treatment of hepatitis C (HCV). The aims of the study were to evaluate the …